TY-JOURA2-Malaguernera-UUU-UHOU-Wang-Wang-SHOU-ZEU-ZHOUAUUUUNENYNEUNEUUUUUEUUUUBYUUELEUEUUUUUUUUUUUUUUUUUUUUUEZHEUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUEUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUIAUIAUIAUIAUAUIAUIAUIAUIAUIAUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUAUUUUUUUUUUUUUUUUUUUUUUUUUAUAUAUAUUUUUUUUUUUAUUUUUUAUAUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUUU 目标 CD89 α IgA受体可分解成综合体血清IgA并参与IgAnephroope临床实践使用结果自相矛盾这项研究旨在调查sCD89-IgA综合体能否帮助诊断或评价该疾病 方法论 .sbandieELISA建立使用反CD89反捕体和HP编译反IgA反检测体sCD89-IgA综合体测试IgAN病人的血清水平时使用这种方法,没有免疫抑制历史和健康对象sCD89-IgA复合值和疾病严重程度之间的关联分析 结果 .SerumsCD89-IgA综合体随年龄增长 P级 < 0.001 )IgAN病人sCD89-IgA复合值比与年龄和性别相匹配正常人高 P级 < 0.001 )srumsCD89-IgAN显性预测IgAN诊断 P级 < 0.001 )sCD89-IgA复合物与基线临床表现物、xford分类或肾功能变速无关 结论 .srumsCD89-IgA复合体可引导没有免疫抑制历史的病人诊断IgAN,但在临床病理预测方面提供有限帮助SN-0278-0240UR-https://doi.org/101155/2020/8393075DO-10.1155/20/8393075JF-HindawiKW-ER